83% of Type 1 Diabetes Patients Stopped Insulin in This Trial

This could be one of the most exciting developments in diabetes research in decades.

On June 22, 2025, a clinical trial published in the New England Journal of Medicine revealed something remarkable:

83% of participants with Type 1 diabetes were able to stop insulin for over a year…

After receiving stem cell–derived therapy.

The treatment is called VX-264.

It works by replacing the body’s lost beta cells—the ones responsible for insulin production.

How?

Scientists encapsulate lab-grown pancreatic islet cells (the insulin-producing kind) and put them back into the body…

Where they restore natural insulin function.

It’s not a cure. Not yet.

But for people living with the burden of daily insulin injections, this study represents a massive step forward.

It’s the first real evidence that beta cell function can be restored safely and sustainably.

Even more encouraging:

There were no serious side effects, according to the study’s lead researcher, Dr. Trevor Reichman.

We’re still in early phases—but the science is promising.

This is the kind of progress that makes you stop and realize what’s possible when research is directed toward root causes, not just symptom management.

It also reinforces a truth we come back to over and over again:

When the body is given the right instructions, it knows how to heal.

Forward this to a friend or family member.

More soon,

Kashif Khan

Not a subscriber? Click here.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease or prescribing any medication. If you have or suspect that you have a medical problem, promptly contact your regular healthcare provider.